Vectors Research Management LLC Purchases 8,502 Shares of Medtronic PLC $MDT

Vectors Research Management LLC lifted its position in Medtronic PLC (NYSE:MDT) by 58.3% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 23,083 shares of the medical technology company’s stock after buying an additional 8,502 shares during the quarter. Vectors Research Management LLC’s holdings in Medtronic were worth $2,198,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Arlington Partners LLC lifted its position in Medtronic by 4.4% during the 3rd quarter. Arlington Partners LLC now owns 54,158 shares of the medical technology company’s stock worth $5,158,000 after acquiring an additional 2,296 shares during the last quarter. Klein Pavlis & Peasley Financial Inc. grew its position in shares of Medtronic by 2.6% in the third quarter. Klein Pavlis & Peasley Financial Inc. now owns 45,133 shares of the medical technology company’s stock valued at $4,298,000 after purchasing an additional 1,140 shares during the last quarter. Community Bank & Trust Waco Texas increased its stake in shares of Medtronic by 2.8% in the third quarter. Community Bank & Trust Waco Texas now owns 18,663 shares of the medical technology company’s stock worth $1,777,000 after purchasing an additional 506 shares during the period. Mainsail Asset Management LLC acquired a new position in shares of Medtronic during the 3rd quarter worth about $220,000. Finally, Csenge Advisory Group lifted its position in shares of Medtronic by 100.0% during the 3rd quarter. Csenge Advisory Group now owns 12,390 shares of the medical technology company’s stock worth $1,180,000 after purchasing an additional 6,195 shares during the last quarter. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Medtronic Stock Down 2.2%

MDT opened at $96.82 on Friday. Medtronic PLC has a fifty-two week low of $79.55 and a fifty-two week high of $106.33. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.42 and a quick ratio of 1.80. The firm’s fifty day moving average price is $98.99 and its two-hundred day moving average price is $94.84. The company has a market capitalization of $124.12 billion, a P/E ratio of 26.10, a P/E/G ratio of 2.61 and a beta of 0.71.

Medtronic (NYSE:MDT) last announced its quarterly earnings data on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.31 by $0.05. Medtronic had a net margin of 13.71% and a return on equity of 14.86%. The company had revenue of $8.96 billion during the quarter, compared to analysts’ expectations of $8.86 billion. During the same quarter in the prior year, the company posted $1.26 EPS. The business’s revenue was up 6.6% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, analysts anticipate that Medtronic PLC will post 5.46 EPS for the current year.

Medtronic Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, January 16th. Shareholders of record on Friday, December 26th were issued a dividend of $0.71 per share. This represents a $2.84 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date of this dividend was Friday, December 26th. Medtronic’s payout ratio is presently 76.55%.

Analysts Set New Price Targets

MDT has been the topic of a number of research analyst reports. Cowen reaffirmed a “buy” rating on shares of Medtronic in a report on Friday, November 14th. UBS Group raised their price objective on shares of Medtronic from $95.00 to $102.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 19th. Citigroup boosted their target price on shares of Medtronic from $101.00 to $112.00 and gave the stock a “buy” rating in a research report on Tuesday, October 7th. The Goldman Sachs Group set a $111.00 target price on shares of Medtronic and gave the company a “neutral” rating in a research note on Wednesday, November 19th. Finally, Wells Fargo & Company raised their price target on shares of Medtronic from $100.00 to $114.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 19th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and eleven have assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $110.28.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).